JP2016513712A - カイロミクロンへの分子の取り込みのためのコレストソーム小胞 - Google Patents

カイロミクロンへの分子の取り込みのためのコレストソーム小胞 Download PDF

Info

Publication number
JP2016513712A
JP2016513712A JP2016502534A JP2016502534A JP2016513712A JP 2016513712 A JP2016513712 A JP 2016513712A JP 2016502534 A JP2016502534 A JP 2016502534A JP 2016502534 A JP2016502534 A JP 2016502534A JP 2016513712 A JP2016513712 A JP 2016513712A
Authority
JP
Japan
Prior art keywords
acid
cholestosome
active agent
cells
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016502534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513712A5 (cg-RX-API-DMAC7.html
Inventor
ジェローム， ジェイ． シェンターク，
ジェローム， ジェイ． シェンターク，
メアリー， ピー． マコート，
メアリー， ピー． マコート，
ローレンス ミエルニッキー，
ローレンス ミエルニッキー，
ジュリー ヒューズ，
ジュリー ヒューズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2016513712(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2016513712A publication Critical patent/JP2016513712A/ja
Publication of JP2016513712A5 publication Critical patent/JP2016513712A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2016502534A 2013-03-14 2014-03-14 カイロミクロンへの分子の取り込みのためのコレストソーム小胞 Ceased JP2016513712A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783003P 2013-03-14 2013-03-14
US61/783,003 2013-03-14
PCT/US2014/027761 WO2014152795A2 (en) 2013-03-14 2014-03-14 Cholestosome vesicles for incorporation of molecules into chylomicrons

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019005894A Division JP6688408B2 (ja) 2013-03-14 2019-01-17 カイロミクロンへの分子の取り込みのためのコレストソーム小胞

Publications (2)

Publication Number Publication Date
JP2016513712A true JP2016513712A (ja) 2016-05-16
JP2016513712A5 JP2016513712A5 (cg-RX-API-DMAC7.html) 2017-04-20

Family

ID=51581747

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502534A Ceased JP2016513712A (ja) 2013-03-14 2014-03-14 カイロミクロンへの分子の取り込みのためのコレストソーム小胞
JP2019005894A Active JP6688408B2 (ja) 2013-03-14 2019-01-17 カイロミクロンへの分子の取り込みのためのコレストソーム小胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019005894A Active JP6688408B2 (ja) 2013-03-14 2019-01-17 カイロミクロンへの分子の取り込みのためのコレストソーム小胞

Country Status (10)

Country Link
US (6) US9693968B2 (cg-RX-API-DMAC7.html)
EP (1) EP2970369B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016513712A (cg-RX-API-DMAC7.html)
CN (1) CN105164143B (cg-RX-API-DMAC7.html)
AU (1) AU2014236559B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015022936A2 (cg-RX-API-DMAC7.html)
CA (1) CA2905108C (cg-RX-API-DMAC7.html)
IL (1) IL241501B (cg-RX-API-DMAC7.html)
MX (1) MX384232B (cg-RX-API-DMAC7.html)
WO (1) WO2014152795A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528294A (ja) * 2016-08-23 2019-10-10 ジェローム， ジェイ． シェンターク， ペプチド、タンパク質及び核酸をカイロミクロン及び体細胞に積載するコレステリルエステル小胞

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119782B2 (en) 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
JP2016513712A (ja) * 2013-03-14 2016-05-16 ジェローム， ジェイ． シェンターク， カイロミクロンへの分子の取り込みのためのコレストソーム小胞
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2016054399A1 (en) * 2014-10-01 2016-04-07 The Brigham And Women's Hospital, Inc. Enhancing dermal wound healing by downregulating microrna-26a
ES2574615B1 (es) * 2014-12-19 2017-07-24 Biopraxis Research Aie Nanopartícula lipídica de tobramicina
AU2016379403B2 (en) 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
CN105797132A (zh) * 2016-05-03 2016-07-27 滨州医学院 沙奎拉韦的医药新用途
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
CN107260681A (zh) * 2017-08-04 2017-10-20 济南维瑞医药科技开发有限公司 一种磷酸特地唑胺脂质体的制备方法及其应用
US12478585B2 (en) 2017-08-09 2025-11-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Micelles and vesicles for the delivery of glycopeptides
WO2019032877A1 (en) * 2017-08-09 2019-02-14 Arizona Board Of Regents On Behalf Of The University Of Arizona MICELLES AND VESICLES FOR RELEASE OF GLYCOPEPTIDES
US12078642B2 (en) * 2017-11-09 2024-09-03 The University Of Melbourne Methods for evaluating and improving cognitive function
CN109929806B (zh) * 2017-12-19 2020-05-08 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
US11911445B2 (en) 2018-01-23 2024-02-27 Gila Therapeutics, Inc. Peptide YY pharmaceutical formulations, compositions, and methods
WO2019148282A1 (en) * 2018-02-01 2019-08-08 The Royal Institution For The Advancement Of Learning/Mcgill University Formulations for improving the delivery of hydrophobic agents
MX2021013842A (es) * 2019-05-14 2022-01-18 Pharmosa Biopharm Inc Composicion farmaceutica de un farmaco de acido debil y metodos de administracion.
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
CN110638788A (zh) * 2019-10-25 2020-01-03 广州医科大学 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023003506A (es) * 2020-09-25 2023-06-28 Algorithm Sciences Inc Composiciones y métodos para la administración de vasodilatadores.
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2023112974A1 (ja) * 2021-12-14 2023-06-22 シード医療製薬株式会社 海藻抽出物を含む高血圧症改善剤並びに同高血圧症改善剤を含む機能性食品、医薬部外品及び医薬品
CN114470186B (zh) * 2022-02-17 2023-10-20 唐颐控股(深圳)有限公司 一种可吸入式纳米新冠疫苗的制备方法
KR20240157096A (ko) 2022-03-23 2024-10-31 나노베이션 테라퓨틱스 인크. 고 스테롤-함유 지질 나노입자
CN119837820B (zh) * 2023-12-13 2025-10-10 上海交通大学 一种基于蛋白载体的活性成分透皮递送系统及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225264A1 (en) * 2006-03-20 2007-09-27 Mccourt Mary P Drug delivery means
US20110166036A1 (en) * 2008-05-22 2011-07-07 H. Lundbeck A/S Modulation of the vps10p-domain for the treatment of cardiovascular disease

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
CA1335348C (en) 1988-03-04 1995-04-25 Yasuaki Ogawa Liposome composition
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1992003123A1 (en) 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
PT937456E (pt) 1998-02-23 2004-10-29 Cilag Ag Int Dispersao lipossomal de eritropoietina
KR100874798B1 (ko) 2002-04-26 2008-12-19 이인규 전사시 ｄｎａ 결합부위를 포함하는 원형의 아령형 디코이올리고뉴클레오티드
CA2752143C (en) * 2002-05-15 2014-09-23 Sutter West Bay Hospitals Delivery of nucleic acid-like compounds
JP4063822B2 (ja) 2003-04-11 2008-03-19 コリアナ・コズメティック・カンパニー・リミテッド 皮膚しわ改善及び皮膚美白の二重機能性化粧料組成物。
CA2524368A1 (en) 2003-05-02 2004-11-18 The Board Of Trustees Of The University Of Illinois Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
WO2004100928A1 (de) 2003-05-09 2004-11-25 Novosom Ag Injizierbare liposomale depots zum wirkstoffdelivery
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
WO2007021822A2 (en) 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
US20100080773A1 (en) * 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
EP2217221B1 (en) * 2007-10-17 2018-06-27 Korea Advanced Institute of Science and Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
CA2723434C (en) * 2008-05-05 2018-01-23 Oramed Ltd. Methods and compositions for oral administration of exenatide
WO2010027498A2 (en) 2008-09-03 2010-03-11 New Science Holdings, Llc Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions
US9757346B2 (en) 2008-09-03 2017-09-12 Volant Holdings Gmbh Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes)
JP2009143963A (ja) 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
US20130273154A1 (en) 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
SG184127A1 (en) 2010-03-19 2012-10-30 Massachusetts Inst Technology Lipid vesicle compositions and methods of use
US20110268653A1 (en) 2010-04-16 2011-11-03 The Board Of Regents Of The University Of Texas System Compositions and Methods Related to Acid Stable Lipid Nanospheres
US8355188B2 (en) 2010-07-27 2013-01-15 Foxlink Image Technology Co., Ltd. Document guiding mechanism
KR102198749B1 (ko) 2011-03-02 2021-01-06 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
JP2014519496A (ja) * 2011-05-11 2014-08-14 ナノヴァレント ファーマシューティカルズ，インコーポレイテッド Ａｌｃａｍ細胞表面受容体を標的とする細胞毒性重合リポソームナノ粒子による増強された骨肉腫の増殖抑制
US9693969B2 (en) 2012-01-02 2017-07-04 Andrew L. SKIGEN Mucous membrane active agent application
EP2830599B1 (en) 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
JP2016513712A (ja) * 2013-03-14 2016-05-16 ジェローム， ジェイ． シェンターク， カイロミクロンへの分子の取り込みのためのコレストソーム小胞
CN105377271A (zh) 2013-03-15 2016-03-02 全技术公司 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
WO2018039303A1 (en) 2016-08-23 2018-03-01 Schentag Jerome J Cholesteryl ester vesicles loading peptides, proteins and nucleic acids into chylomicrons and body cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225264A1 (en) * 2006-03-20 2007-09-27 Mccourt Mary P Drug delivery means
US20110166036A1 (en) * 2008-05-22 2011-07-07 H. Lundbeck A/S Modulation of the vps10p-domain for the treatment of cardiovascular disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "UNDERGRADUATE RESEARCH SYMPOSIUM", WNY ACS UNDERGRADUATE RESEARCH SYMPOSIUM, JPN6018010586, 2010, pages 1 - 40, ISSN: 0003764866 *
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 34, no. 2, JPN6018010585, 2008, pages 134 - 141, ISSN: 0003764865 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528294A (ja) * 2016-08-23 2019-10-10 ジェローム， ジェイ． シェンターク， ペプチド、タンパク質及び核酸をカイロミクロン及び体細胞に積載するコレステリルエステル小胞

Also Published As

Publication number Publication date
US12005146B2 (en) 2024-06-11
US12465575B2 (en) 2025-11-11
IL241501A0 (en) 2015-11-30
US11052052B2 (en) 2021-07-06
EP2970369A4 (en) 2016-10-12
MX2015011462A (es) 2016-05-31
AU2014236559B2 (en) 2020-03-12
US20220040116A1 (en) 2022-02-10
US20200069598A1 (en) 2020-03-05
US10369114B2 (en) 2019-08-06
WO2014152795A3 (en) 2014-11-27
IL241501B (en) 2020-05-31
US20180055780A1 (en) 2018-03-01
MX384232B (es) 2025-03-14
EP2970369B1 (en) 2023-11-22
US20160030361A1 (en) 2016-02-04
CA2905108A1 (en) 2014-09-25
US11633364B2 (en) 2023-04-25
CN105164143A (zh) 2015-12-16
JP6688408B2 (ja) 2020-04-28
CA2905108C (en) 2021-12-07
US20240398719A1 (en) 2024-12-05
AU2014236559A1 (en) 2018-05-24
HK1212354A1 (en) 2016-06-10
CN105164143B (zh) 2019-02-19
US20230277471A1 (en) 2023-09-07
US9693968B2 (en) 2017-07-04
WO2014152795A2 (en) 2014-09-25
BR112015022936A2 (pt) 2017-07-18
EP2970369A2 (en) 2016-01-20
JP2019070031A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
US12465575B2 (en) Methods of treatment using cholestosome vesicles for incorporation of molecules into chylomicrons
Vargason et al. The evolution of commercial drug delivery technologies
Dong et al. Comparative study of mucoadhesive and mucus-penetrative nanoparticles based on phospholipid complex to overcome the mucus barrier for inhaled delivery of baicalein
US20230240997A1 (en) Method of treating cancer
EP2135600B1 (en) Targeting agent for cancer cell or cancer-associated fibroblast
Fan et al. Lipid-based nanoparticles for cancer immunotherapy
Fan et al. Advances in inhaled nanoparticle drug delivery for pulmonary disease management
Zhao et al. Small extracellular vesicles encapsulating lefty1 mRNA inhibit hepatic fibrosis
JP6302531B2 (ja) 生体投与を目的とした薬物導入剤および製造方法
WO2012059936A1 (en) Pharmaceutical compositions for colloidal drug delivery
HK1212354B (en) Cholestosome vesicles for incorporation of molecules into chylomicrons
CN111315399A (zh) 用于药物递送的葡萄糖敏感性组合物
Guo et al. Functional shell engineering of bioactive wheat-seedling nanovesicles with chitosan derivatives for synergistic metabolic therapy via enhanced oral delivery
US20260083770A1 (en) Rna complexes and nanostructures for treatment of cancer metastasis
Verma et al. An overview of novel formulations for ocular viral infections: focused on nanomedicines
WO2025097049A1 (en) Rna-sn-38 conjugate for the treatment of colorectal cancer and sequential lung metastasis
Amiji et al. Therapeutic nanomedicine: Polymeric nanosystems for drug and gene delivery
Jana et al. Delivery Systems for Proteins and Peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180926

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181219

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20190325